This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Association of the CCR532 Mutation With Improved Response to Antiretroviral Therapy

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Individuals infected with human immunodeficiency virus type 1 (HIV-1) who are treated with highly active antiretroviral therapy (HAART), including HIV-1 protease inhibitors, experience dramatic benefits.¹ However, virologic failure occurs commonly in clinical trials and in practice.^2-3 The CCR532 mutation is associated with decreased susceptibility to HIV-1 infection (32/32) and slower progression to acquired immunodeficiency syndrome (wild type [wt]/32).⁴ We wished to determine whether the presence of the CCR532 allele would affect virologic outcome after HAART is initiated.

Methods

We studied patients (N=293) who were prescribed a treatment regimen that included an HIV-1 protease inhibitor between June 1995 and December 1997. Virologic success was defined as plasma HIV-1 RNA level of less than 400 copies/mL at the last clinic visit. (We previously found that 82% of patients who missed more than 1 clinic visit the year prior to protease . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes
Kawamura et al.
J. Virol. 2004;78:7602-7609.
ABSTRACT | FULL TEXT  

Distribution of Chemokine Receptor CCR2 and CCR5 Genotypes and Their Relative Contribution to Human Immunodeficiency Virus Type 1 (HIV-1) Seroconversion, Early HIV-1 RNA Concentration in Plasma, and Later Disease Progression
Tang et al.
J. Virol. 2002;76:662-672.
ABSTRACT | FULL TEXT  

Effects of CCR5-{Delta} 32, CCR2-64I, and SDF-1 3'A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data
Ioannidis et al.
ANN INTERN MED 2001;135:782-795.
ABSTRACT | FULL TEXT